Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension (RHT)
Efficacy and Safety of Low Intensity- Extracorporeal Shockwave Therapy in Drug Resistant Hypertension
Low intensity shockwaves have been proven in animal and human studies to increase tissue perfusion, promote angiogenesis and tissue regeneration and improve neural function.
The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with resistant hypertension.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Ayelet Shauer, MD
- Phone Number: +972-2-6776564
- Email: aye.shauer@gmail.com
Study Locations
-
-
-
Jerusalem, Israel, 91120
- Hadassah Medical Organization
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects who have provided written informed consent.
- Age ≥18 and ≤80 years old.
- Office systolic blood pressure that remains ≥160 mmHg (≥150 mmHg for patient with type 2 diabetes) despite the stable use of ≥3 antihypertensive medications concurrently at maximally tolerated doses, of which one is a diuretic (unless there is a tolerance or a contraindication for a diuretics).
- Able and willing to comply with the required follow-up schedule.
Exclusion Criteria:
- Subjects who have participated in a clinical study involving another investigational drug or device within 4 weeks prior to Screening.
- Have hypertension secondary to an identifiable and treatable cause or take medication that can raise the BP.
- Prior renal artery intervention (balloon angioplasty or stenting).
- Pregnancy.
- Uncompensated heart failure.
- Chronic Liver Disease.
- Patients with skin wound / infection at the treatment area.
- Subjects who take oral anti-coagulants.
- Local tumor of treatment area.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treated Group
This group will receive actual shockwave treatment
|
Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ambulatory Blood Pressure Monitoring (ABPM)
Time Frame: 6 Months
|
Change in 24 hour ambulatory blood pressure (ABPM) from baseline to six months post last treatment (± 2 weeks)
|
6 Months
|
|
Ambulatory Blood Pressure Monitoring (ABPM)
Time Frame: 3 Months
|
Change in 24 hour ambulatory blood pressure (ABPM) from baseline to three months post last treatment (± 2 weeks)
|
3 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Events
Time Frame: 6 Months
|
6 Months
|
|
|
Office Blood Pressure
Time Frame: 6 Months
|
Change in office blood pressure from baseline to three months and six months post last treatment (± 2 weeks).
|
6 Months
|
|
Serum Urea and Creatinine
Time Frame: 3 Months
|
Change in serum urea and creatinine from baseline to 3 months and 6 months (± 2 weeks) post last treatment
|
3 Months
|
|
Ultrasound
Time Frame: 3 Months
|
Change in ultrasound-measured renal resistive index (RRI)
|
3 Months
|
|
Serum Urea and Creatinine
Time Frame: 6 Months
|
Change in serum urea and creatinine from baseline to 3 months and 6 months (± 2 weeks) post last treatment
|
6 Months
|
|
Office Blood Pressure
Time Frame: 3 Months
|
Change in office blood pressure from baseline to three months and six months post last treatment (± 2 weeks).
|
3 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ayelet Shauer, MD, Hadassah Medical Organization
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RHT-01
- 0449-13 (Other Identifier: The Department of Clinical Trials - Israel, Hadassah Helsinki Committee)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.